Skip to main content

and
  1. Article

    Open Access

    Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

    The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unc...

    Antoni Bayes-Genis, Oriol Iborra-Egea, Giosafat Spitaleri in Scientific Reports (2021)

  2. No Access

    Article

    Preload dependence of pulmonary haemodynamics and right ventricular performance

    Systolic pulmonary artery pressure (SPAP) and right heart adaptation in relation to pre-existing preload are often disregarded. To determine volume-related changes in the pulmonary-right ventricle (RV) unit an...

    Francisco Gual-Capllonch, Josep Lupón, Ioana Bancu in Clinical Research in Cardiology (2021)

  3. Article

    Open Access

    Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018

    To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients from different etiologies with depressed and preserved LVEF. A total of 2368 consecutive patients with HF (...

    Giosafat Spitaleri, Josep Lupón, Mar Domingo, Evelyn Santiago-Vacas in Scientific Reports (2021)

  4. Article

    Open Access

    Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline

    Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis i...

    María Teresa Julián, Núria Alonso, Josep Lupón in Cardiovascular Diabetology (2020)